U.S. FDA Approves Pfizer's XELJANZ® for the Treatment of Active Ankylosing Spondylitis Pharmaceutical Investing
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Arena Pharmaceuticals Inc. Buyout Life Science Investing
Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics' TCR Bispecific Program IMA401 Pharmaceutical Investing
Pfizer Announces Additional Phase 2/3 Study Results Confirming Robust Efficacy of Novel COVID-19 Oral Antiviral Treatment Candidate in Reducing Risk of Hospitalization or Death Pharmaceutical Investing
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Arena Pharmaceuticals, Inc. Life Science Investing
Merck Announces Clinical Holds on Studies Evaluating Islatravir for the Treatment and Prevention of HIV-1 Infection Pharmaceutical Investing
Yescarta® ZUMA-12 Study Demonstrates 78% Complete Response Rate as Part of First-Line Treatment in Newly Diagnosed High-Risk Large B-Cell Lymphoma Pharmaceutical Investing
ARENA PHARMACEUTICALS ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of ARNA and Encourages Investors to Contact the Firm Life Science Investing
Lobe Sciences Announces That Its Shares Will Trade on the OTCQB Market in the United States Pharmaceutical Investing
